The effects of obesity-related peptides on the vasculature

Current Vascular Pharmacology

Volumn 4, Issue 1, 2006, Pages 79-85

  Skilton, Michael R ^a   Celermajer, David S ^a,b  

^a UNIVERSITY OF SYDNEY   (Australia)

^b ROYAL PRINCE ALFRED HOSPITAL   (Australia)

Author keywords

Adipocytokines; Adiponectin; Atherosclerosis; Leptin; Neuropeptide Y; Obesity; Resistin; Vascular biology

Indexed keywords

ADIPOCYTOKINE; ADIPONECTIN; GHRELIN; INTERLEUKIN 1BETA; LEPTIN; LEPTIN RECEPTOR; NEUROPEPTIDE Y; RESISTIN; TUMOR NECROSIS FACTOR ALPHA; PEPTIDE HORMONE;

ATHEROGENESIS; ATHEROSCLEROSIS; CARDIOVASCULAR DISEASE; DISEASE COURSE; ENERGY BALANCE; ENERGY METABOLISM; HUMAN; INFLAMMATION; MORBIDITY; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; OBESITY; REVIEW; VASCULARIZATION; WEIGHT REDUCTION; ADIPOSE TISSUE; DRUG EFFECT; METABOLISM; PHYSIOLOGY; VASCULAR SMOOTH MUSCLE;

ADIPONECTIN; ADIPOSE TISSUE; ATHEROSCLEROSIS; DIABETES MELLITUS, TYPE 2; HUMANS; LEPTIN; MUSCLE, SMOOTH, VASCULAR; OBESITY; PEPTIDE HORMONES;

EID: 33644853079     PISSN: 15701611     EISSN: None     Source Type: Journal    
DOI: 10.2174/157016106775203135     Document Type: Review

References (95)

1. Mokdad AH, Ford ES, Bowman BA, Dietz WH, Vinicor F, Bales VS, et al. Prevalence of obesity, diabetes, and obesity-related health risk factors, 2001. JAMA 2003; 289: 76-9.
2. Cooke JP and Oka RK. Does leptin cause vascular disease? Circulation 2002; 106: 1904-5.
3. Matsuda M, Shimomura I, Sata M, Arita Y, Nishida M, Maeda N, et al. Role of adiponectin in preventing vascular stenosis. The missing link of adipo-vascular axis. J Biol Chem 2002; 277: 37487-91.
4. Blankenberg S, Barbaux S and Tiret L. Adhesion molecules and atherosclerosis. Atherosclerosis 2003; 170: 191-203.
5. Alexander RW and Dzau VJ. Vascular biology: the past 50 years. Circulation 2000; 102: IV112-6.
6. Libby P, Ridker PM and Maseri A. Inflammation and atherosclerosis. Circulation 2002; 105: 1135-43.
7. Libby P. Molecular bases of the acute coronary syndromes. Circulation 1995; 91: 2844-50.
8. Zhang Y, Proenca R, Maffei M, Barone M, Leopold L and Friedman JM. Positional cloning of the mouse obese gene and its human homologue. Nature 1994; 372: 425-32.
9. Pelleymounter MA, Cullen MJ, Baker MB, Hecht R, Winters D, Boone T, et al. Effects of the obese gene product on body weight regulation in ob/ob mice. Science 1995; 269: 540-3.
10. Weigle DS, Bukowski TR, Foster DC, Holderman S, Kramer JM, Lasser G, et al. Recombinant ob protein reduces feeding and body weight in the ob/ob mouse. J Clin Invest 1995; 96: 2065-70.
11. Maffei M, Halaas J, Ravussin E, Pratley RE, Lee GH, Zhang Y, et al. Leptin levels in human and rodent: measurement of plasma leptin and ob RNA in obese and weight-reduced subjects. Nat Med 1995; 1: 1155-61.
12. Hamann A and Matthaei S. Regulation of energy balance by leptin. Exp Clin Endocrinol Diabetes 1996; 104: 293-300.
13. Wallace AM, McMahon AD, Packard CJ, Kelly A, Shepherd J, Gaw A, et al. Plasma leptin and the risk of cardiovascular disease in the west of Scotland coronary prevention study (WOSCOPS). Circulation 2001; 104: 3052-6.
14. Couillard C, Lamarche B, Mauriege P, Cantin B, Dagenais GR, Moorjani S, et al. Leptinemia is not a risk factor for ischemic heart disease in men. Prospective results from the Quebec Cardiovascular Study. Diabetes Care 1998; 21: 782-6.
15. Singhal A, Farooqi IS, Cole TJ, O'Rahilly S, Fewtrell M, Kattenhorn M, et al. Influence of leptin on arterial distensibility: a novel link between obesity and cardiovascular disease? Circulation 2002; 106: 1919-24.
16. Tounian P, Aggoun Y, Dubern B, Varille V, Guy-Grand B, Sidi D, et al. Presence of increased stiffness of the common carotid artery and endothelial dysfunction in severely obese children: a prospective study. Lancet 2001; 358: 1400-4.
17. Cohn JN. Arterial compliance to stratify cardiovascular risk: more precision in therapeutic decision making. Am J Hypertens 2001; 14: 258S-63S.
18. Atabek ME, Kurtoglu S, Demir F and Baykara M. Relation of serum leptin and insulin-like growth factor-1 levels to intima-media thickness and functions of common carotid artery in children and adolescents with type 1 diabetes. Acta Paediatr 2004; 93: 1052-7.
19. van den Beld AW, Bots ML, Janssen JA, Pols HA, Lamberts SW and Grobbee DE. Endogenous hormones and carotid atherosclerosis in elderly men. Am J Epidemiol 2003; 157: 25-31.
20. Ciccone M, Vettor R, Pannacciulli N, Minenna A, Bellacicco M, Rizzon P, et al. Plasma leptin is independently associated with the intima-media thickness of the common carotid artery. Int J Obes Relat Metab Disord 2001; 25: 805-10.
21. Bodary PF, Westrick RJ, Wickenheiser KJ, Shen Y and Eitzman DT. Effect of leptin on arterial thrombosis following vascular injury in mice. JAMA 2002; 287: 1706-9.
22. Konstantinides S, Schafer K, Koschnick S and Loskutoff DJ. Leptin-dependent platelet aggregation and arterial thrombosis suggests a mechanism for atherothrombotic disease in obesity. J Clin Invest 2001; 108: 1533-40.
23. Porreca E, Di Febbo C, Moretta V, Angelini A, Guglielmi MD, Di Nisio M, et al. Circulating leptin is associated with oxidized LDL in postmenopausal women. Atherosclerosis 2004; 175: 139-43.
24. Bouloumie A, Marumo T, Lafontan M and Busse R. Leptin induces oxidative stress in human endothelial cells. FASEB J 1999; 13: 1231-8.
25. Yamagishi SI, Edelstein D, Du XL, Kaneda Y, Guzman M and Brownlee M. Leptin induces mitochondrial superoxide production and monocyte chemoattractant protein-1 expression in aortic endothelial cells by increasing fatty acid oxidation via protein kinase A. J Biol Chem 2001; 276: 25096-100.
26. Porreca E, Di Febbo C, Fusco L, Moretta V, Di Nisio M and Cuccurullo F. Soluble thrombomodulin and vascular adhesion molecule-1 are associated to leptin plasma levels in obese women. Atherosclerosis 2004; 172: 175-80.
27. Kimura K, Tsuda K, Baba A, Kawabe T, Boh-oka S, Ibata M, et al. Involvement of nitric oxide in endothelium-dependent arterial relaxation by leptin. Biochem Biophys Res Commun 2000; 273: 745-9.
28. Lembo G, Vecchione C, Fratta L, Marino G, Trimarco V, d'Amati G, et al. Leptin induces direct vasodilation through distinct endothelial mechanisms. Diabetes 2000; 49: 293-7.
29. Nakagawa K, Higashi Y, Sasaki S, Oshima T, Matsuura H and Chayama K. Leptin causes vasodilation in humans. Hypertens Res 2002; 25: 161-5.
30. Matsuda K, Teragawa H, Fukuda Y, Nakagawa K, Higashi Y and Chayama K. Leptin causes nitric-oxide independent coronary artery vasodilation in humans. Hypertens Res 2003; 26: 147-52.
31. Maeda K, Okubo K, Shimomura I, Funahashi T, Matsuzawa Y and Matsubara K. cDNA cloning and expression of a novel adipose specific collagen-like factor, apM1 (AdiPose Most abundant Gene transcript 1). Biochem Biophys Res Commun 1996; 221: 286-9.
32. Nakano Y, Tobe T, Choi-Miura NH, Mazda T and Tomita M. Isolation and characterization of GBP28, a novel gelatin-binding protein purified from human plasma. J Biochem (Tokyo) 1996; 120: 803-12.
33. Scherer PE, Williams S, Fogliano M, Baldini G and Lodish HF. A novel serum protein similar to C1q, produced exclusively in adipocytes. J Biol Chem 1995; 270: 26746-9.
34. Hu E, Liang P and Spiegelman BM. AdipoQ is a novel adipose-specific gene dysregulated in obesity. J Biol Chem 1996; 271: 10697-703.
35. Dzielinska Z, Januszewicz A, Wiecek A, Demkow M, Makowiecka-Ciesla M, Prejbisz A, et al. Decreased plasma concentration of a novel anti-inflammatory protein - adiponectin - in hypertensive men with coronary artery disease. Thromb Res 2003; 110: 365-9.
36. Kumada M, Kihara S, Sumitsuji S, Kawamoto T, Matsumoto S, Ouchi N, et al. Association of hypoadiponectinemia with coronary artery disease in men. Arterioscler Thromb Vasc Biol 2003; 23: 85-9.
37. Yamauchi T, Kamon J, Ito Y, Tsuchida A, Yokomizo T, Kita S, et al. Cloning of adiponectin receptors that mediate antidiabetic metabolic effects. Nature 2003; 423: 762-9.
38. Chinetti G, Zawadski C, Fruchart JC and Staels B. Expression of adiponectin receptors in human macrophages and regulation by agonists of the nuclear receptors PPARalpha, PPARgamma, and LXR. Biochem Biophys Res Commun 2004; 314: 151-8.
39. Arita Y, Kihara S, Ouchi N, Takahashi M, Maeda K, Miyagawa J, et al. Paradoxical decrease of an adipose-specific protein, adiponectin, in obesity. Biochem Biophys Res Commun 1999; 257: 79-83.
40. Duncan BB, Schmidt MI, Pankow JS, Bang H, Couper D, Ballantyne CM, et al. Adiponectin and the development of type 2 diabetes: the atherosclerosis risk in communities study. Diabetes 2004; 53: 2473-8.
41. Pischon T, Girman CJ, Hotamisligil GS, Rifai N, Hu FB and Rimm EB. Plasma adiponectin levels and risk of myocardial infarction in men. Jama 2004; 291: 1730-7.
42. Shimabukuro M, Higa N, Asahi T, Oshiro Y, Takasu N, Tagawa T, et al. Hypoadiponectinemia is closely linked to endothelial dysfunction in man. J Clin Endocrinol Metab 2003; 88: 3236-40.
43. Ouchi N, Ohishi M, Kihara S, Funahashi T, Nakamura T, Nagaretani H, et al. Association of hypoadiponectinemia with impaired vasoreactivity. Hypertension 2003; 42: 231-4.
44. Okamoto Y, Kihara S, Ouchi N, Nishida M, Arita Y, Kumada M, et al. Adiponectin reduces atherosclerosis in apolipoprotein E-deficient mice. Circulation 2002; 106: 2767-70.
45. Yamauchi T, Kamon J, Waki H, Imai Y, Shimozawa N, Hioki K, et al. Globular adiponectin protected ob/ob mice from diabetes and ApoE-deficient mice from atherosclerosis. J Biol Chem 2003; 278: 2461-8.
46. Hattori Y, Suzuki M, Hattori S and Kasai K. Globular adiponectin upregulates nitric oxide production in vascular endothelial cells. Diabetologia 2003; 46: 1543-9.
47. Motoshima H, Wu X, Mahadev K and Goldstein BJ. Adiponectin suppresses proliferation and superoxide generation and enhances eNOS activity in endothelial cells treated with oxidized LDL. Biochem Biophys Res Commun 2004; 315: 264-71.
48. Ouchi N, Kihara S, Arita Y, Maeda K, Kuriyama H, Okamoto Y , et al. Novel modulator for endothelial adhesion molecules: adipocyte-derived plasma protein adiponectin. Circulation 1999; 100: 2473-6.
49. Kumada M, Kihara S, Ouchi N, Kobayashi H, Okamoto Y, Ohashi K, et al. Adiponectin specifically increased tissue inhibitor of metalloproteinase-1 through interleukin-10 expression in human macrophages. Circulation 2004; 109: 2046-9.
50. Furukawa K, Hori M, Ouchi N, Kihara S, Funahashi T, Matsuzawa Y, et al. Adiponectin down-regulates acyl-coenzyme A:cholesterol acyltransferase-1 in cultured human monocyte-derived macrophages. Biochem Biophys Res Commun 2004; 317: 831-6.
51. Ouchi N, Kihara S, Arita Y, Nishida M, Matsuyama A, Okamoto Y, et al. Adipocyte-derived plasma protein, adiponectin, suppresses lipid accumulation and class A scavenger receptor expression in human monocyte-derived macrophages. Circulation 2001; 103: 1057-63.
52. Ouchi N, Kihara S, Arita Y, Nishida M, Matsuyama A, Okamoto Y, et al. Adipocyte-derived plasma protein, adiponectin, suppresses lipid accumulation and class A scavenger receptor expression in human monocyte-derived macrophages. Circulation 2001; 103: 1057-63.
53. Steppan CM, Bailey ST, Bhat S, Brown EJ, Banerjee RR, Wright CM, et al. The hormone resistin links obesity to diabetes. Nature 2001; 409: 307-12.
54. Nagaev I and Smith U. Insulin resistance and type 2 diabetes are not related to resistin expression in human fat cells or skeletal muscle. Biochem Biophys Res Commun 2001; 285: 561-4.
55. Savage DB, Sewter CP, Klenk ES, Segal DG, Vidal-Puig A, Considine RV, et al. Resistin / Fizz3 expression in relation to obesity and peroxisome proliferator-activated receptor-gamma action in humans. Diabetes 2001; 50: 2199-202.
56. Harsch IA, Koebnick C, Wallaschofski H, Schahin SP, Hahn EG, Ficker JH, et al. Resistin levels in patients with obstructive sleep apnoea syndrome - the link to subclinical inflammation? Med Sci Monit 2004; 10: CR510-CR15.
57. Lee JH, Chan JL, Yiannakouris N, Kontogianni M, Estrada E, Seip R, et al. Circulating resistin levels are not associated with obesity or insulin resistance in humans and are not regulated by fasting or leptin administration: cross-sectional and interventional studies in normal, insulin-resistant, and diabetic subjects. J Clin Endocrinol Metab 2003; 88: 4848-56.
58. Heilbronn LK, Rood J, Janderova L, Albu JB, Kelley DE, Ravussin E, et al. Relationship between serum resistin concentrations and insulin resistance in nonobese, obese, and obese diabetic subjects. J Clin Endocrinol Metab 2004; 89: 1844-8.
59. Degawa-Yamauchi M, Bovenkerk JE, Juliar BE, Watson W, Kerr K, Jones R, et al. Serum resistin (FIZZ3) protein is increased in obese humans. J Clin Endocrinol Metab 2003; 88: 5452-5.
60. Zhang JL, Qin YW, Zheng X, Qiu JL and Zou DJ. Serum resistin level in essential hypertension patients with different glucose tolerance. Diabet Med 2003; 20: 828-31.
61. Youn BS, Yu KY, Park HJ, Lee NS, Min SS, Youn MY, et al. Plasma resistin concentrations measured by enzyme-linked immunosorbent assay using a newly developed monoclonal antibody are elevated in individuals with type 2 diabetes mellitus. J Clin Endocrinol Metab 2004; 89: 150-6.
62. Fehmann HC and Heyn J. Plasma resistin levels in patients with type 1 and type 2 diabetes mellitus and in healthy controls. Horm Metab Res 2002; 34: 671-3.
63. Fujinami A, Obayashi H, Ohta K, Ichimura T, Nishimura M, Matsui H, et al. Enzyme-linked immunosorbent assay for circulating human resistin: resistin concentrations in normal subjects and patients with type 2 diabetes. Clin Chim Acta 2004; 339: 57-63.
64. Stejskal D, Adamovska S, Bartek J, Jurakova R and Proskova J. Resistin - concentrations in persons with type 2 diabetes mellitus and in individuals with acute inflammatory disease. Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub 2003; 147: 63-9.
65. Vendrell J, Broch M, Vilarrasa N, Molina A, Gomez JM, Gutierrez C, et al. Resistin, adiponectin, ghrelin, leptin, and proinflammatory cytokines: relationships in obesity. Obes Res 2004; 12: 962-71.
66. Azuma K, Katsukawa F, Oguchi S, Murata M, Yamazaki H, Shimada A, et al. Correlation between serum resistin level and adiposity in obese individuals. Obes Res 2003; 11: 997-1001.
67. Zhang J, Qin Y, Zheng X, Qiu J, Gong L, Mao H, et al. [The relationship between human serum resistin level and body fat content, plasma glucose as well as blood pressure]. Zhonghua Yi Xue Za Zhi 2002; 82: 1609-12.
68. Gomez-Ambrosi J and Fruhbeck G. Do resistin and resistin-like molecules also link obesity to inflammatory diseases? Ann Intern Med 2001; 135: 306-7.
69. Shetty GK, Economides PA, Horton ES, Mantzoros CS and Veves A. Circulating adiponectin and resistin levels in relation to metabolic factors, inflammatory markers, and vascular reactivity in diabetic patients and subjects at risk for diabetes. Diabetes Care 2004; 27: 2450-7.
70. Kawanami D, Maemura K, Takeda N, Harada T, Nojiri T, Imai Y, et al. Direct reciprocal effects of resistin and adiponectin on vascular endothelial cells: a new insight into adipocytokine-endothelial cell interactions. Biochem Biophys Res Commun 2004; 314: 415-9.
71. Fasshauer M, Klein J, Neumann S, Eszlinger M and Paschke R. Tumor necrosis factor alpha is a negative regulator of resistin gene expression and secretion in 3T3-L1 adipocytes. Biochem Biophys Res Commun 2001; 288: 1027-31.
72. Li Y, Totsune K, Takeda K, Furuyama K, Shibahara S and Takahashi K. Differential expression of adrenomedullin and resistin in 3T3-L1 adipocytes treated with tumor necrosis factor-alpha. Eur J Endocrinol 2003; 149: 231-8.
73. Kaser S, Kaser A, Sandhofer A, Ebenbichler CF, Tilg H and Patsch JR. Resistin messenger-RNA expression is increased by proinflammatory cytokines in vitro. Biochem Biophys Res Commun 2003; 309: 286-90.
74. Verma S, Li SH, Wang CH, Fedak PW, Li RK, Weisel RD, et al. Resistin promotes endothelial cell activation: further evidence of adipokine-endothelial interaction. Circulation 2003; 108: 736-40.
75. Kojima M, Hosoda H, Date Y, Nakazato M, Matsuo H and Kangawa K. Ghrelin is a growth-hormone-releasing acylated peptide from stomach. Nature 1999; 402: 656-60.
76. Cummings DE, Weigle DS, Frayo RS, Breen PA, Ma MK, Dellinger EP, et al. Plasma ghrelin levels after diet-induced weight loss or gastric bypass surgery. N Engl J Med 2002; 346: 1623-30.
77. Otto B, Cuntz U, Fruehauf E, Wawarta R, Folwaczny C, Riepl RL, et al. Weight gain decreases elevated plasma ghrelin concentrations of patients with anorexia nervosa. Eur J Endocrinol 2001; 145: 669-73.
78. DelParigi A, Tschop M, Heiman ML, Salbe AD, Vozarova B, Sell SM, et al. High circulating ghrelin: a potential cause for hyperphagia and obesity in prader-willi syndrome. J Clin Endocrinol Metab 2002; 87: 5461-4.
79. Haqq AM, Farooqi IS, O'Rahilly S, Stadler DD, Rosenfeld RG, Pratt KL, et al. Serum ghrelin levels are inversely correlated with body mass index, age, and insulin concentrations in normal children and are markedly increased in Prader-Willi syndrome. J Clin Endocrinol Metab 2003; 88: 174-8.
80. Gnanapavan S, Kola B, Bustin SA, Morris DG, McGee P, Fairclough P, et al. The tissue distribution of the mRNA of ghrelin and subtypes of its receptor, GHS-R, in humans. J Clin Endocrinol Metab 2002; 87: 2988.
81. Poykko SM, Kellokoski E, Horkko S, Kauma H, Kesaniemi YA and Ukkola O. Low plasma ghrelin is associated with insulin resistance, hypertension, and the prevalence of type 2 diabetes. Diabetes 2003; 52: 2546-53.
82. Fagerberg B, Hulten LM and Hulthe J. Plasma ghrelin, body fat, insulin resistance, and smoking in clinically healthy men: the atherosclerosis and insulin resistance study. Metabolism 2003; 52: 1460-3.
83. Okumura H, Nagaya N, Enomoto M, Nakagawa E, Oya H and Kangawa K. Vasodilatory effect of ghrelin, an endogenous Peptide from the stomach. J Cardiovasc Pharmacol 2002; 39: 779-83.
84. Wiley KE and Davenport AP. Comparison of vasodilators in human internal mammary artery: ghrelin is a potent physiological antagonist of endothelin-1. Br J Pharmacol 2002; 136: 1146-52.
85. Shimizu Y, Nagaya N, Teranishi Y, Imazu M, Yamamoto H, Shokawa T, et al. Ghrelin improves endothelial dysfunction through growth hormone-independent mechanisms in rats. Biochem Biophys Res Commun 2003; 310: 830-5.
86. Pemberton CJ, Tokola H, Bagi Z, Koller A, Pontinen J, Ola A, et al. Ghrelin induces vasoconstriction in the rat coronary vasculature without altering cardiac peptide secretion. Am J Physiol Heart Circ Physiol 2004; 287: H1522-9.
87. Li WG, Gavrila D, Liu X, Wang L, Gunnlaugsson S, Stoll LL, et al. Ghrelin inhibits proinflammatory responses and nuclear factor-kappaB activation in human endothelial cells. Circulation 2004; 109: 2221-6.
88. Dixit VD, Schaffer EM, Pyle RS, Collins GD, Sakthivel SK, Palaniappan R, et al. Ghrelin inhibits leptin- and activation-induced proinflammatory cytokine expression by human monocytes and T cells. J Clin Invest 2004; 114: 57-66.
89. Beaumont NJ, Skinner VO, Tan TM, Ramesh BS, Byrne DJ, MacColl GS, et al. Ghrelin can bind to a species of high density lipoprotein associated with paraoxonase. J Biol Chem 2003; 278: 8877-80.
90. Dinarello CA. Proinflammatory cytokines. Chest 2000; 118: 503-8.
91. Ziccardi P, Nappo F, Giugliano G, Esposito K, Marfella R, Cioffi M, et al. Reduction of inflammatory cytokine concentrations and improvement of endothelial functions in obese women after weight loss over one year. Circulation 2002; 105: 804-9.
92. Zukowska Z, Pons J, Lee EW and Li L. Neuropeptide Y: a new mediator linking sympathetic nerves, blood vessels and immune system? Can J Physiol Pharmacol 2003; 81: 89-94.
93. Karvonen MK, Pesonen U, Koulu M, Niskanen L, Laakso M, Rissanen A, et al. Association of a leucine(7)-to-proline(7) polymorphism in the signal peptide of neuropeptide Y with high serum cholesterol and LDL cholesterol levels. Nat Med 1998; 4: 1434-7.
94. Niskanen L, Karvonen MK, Valve R, Koulu M, Pesonen U, Mercuri M, et al. Leucine 7 to proline 7 polymorphism in the neuropeptide Y gene is associated with enhanced carotid atherosclerosis in elderly patients with type 2 diabetes and control subjects. J Clin Endocrinol Metab 2000; 85: 2266-9.
95. Jarvisalo MJ, Jartti L, Karvonen MK, Pesonen U, Koulu M, Marniemi J, et al. Enhanced endothelium-dependent vasodilation in subjects with Proline7 substitution in the signal peptide of neuropeptide Y. Atherosclerosis 2003; 167: 319-26.